Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center

Chemotherapy

Volumn 57, Issue 1, 2011, Pages 7-11

  Fahimi, Fanak ^a,b,d   Kobarfard, Farzad ^d   Tabarsi, Payam ^b   Hemmati, Shabnam ^d   Salamzadeh, Jamshid ^d   Baniasadi, Shadi ^a,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Isoniazid; Serum isoniazid; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; DRUG BLOOD LEVEL; FEMALE; GENDER; HUMAN; IRAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BODY WEIGHT; DRUG MONITORING; FEMALE; HOSPITALS, CHRONIC DISEASE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; SEX FACTORS; SMOKING; TUBERCULOSIS, PULMONARY;

EID: 78649500342     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321045     Document Type: Article

References (24)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021. (Pubitemid 36548927)
2. Li J, Burzynski JN, Lee YA, Berg D, Driver CR, Ridzon R, Munsiff SS: Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004;126:1770-1776. (Pubitemid 39643978)
3. TB country profile. http://apps.who.int/globalatlas/predefinedReports/TB/ PDF-Files/irn.pdf (accessed November 2009).
4. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE: Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-1183. (Pubitemid 28223801)
5. Ramazanzadeh R, Farnia P, Amirmozafari N, Ghazi F, Ghadertotonchi Z, Kamran J, Mohammadi F, Mirsaedi M, Masjedi M: Comparison between molecular epidemiology, geographical regions and drug resistance in Mycobacterium tuberculosis strains isolated from Iranian and Afghan patients. Chemotherapy 2006;52:316-320.
6. Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA: The most predominant Spoligopatterns of Mycobacterium tuberculosis isolates among Iranian, Afghan-immigrant, Pakistani and Turkish tuberculosis patients: a comparative analysis. Chemotherapy 2010;56:248-257.
7. Velayati AA, Farnia P, Ibrahim TA, Haroun RZ, Kuan HO, Ghanavi J, Farnia P, Kabarei AN, Tabarsi P, Omar AR, Varahram M, Masjedi MR: Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy 2009;55:303-307.
8. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S: Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res 2005;51:353-358. (Pubitemid 40430809)
9. Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA: First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran - eight years of surveillance. Int J Infect Dis 2009;13:e236-e240.
10. World Health Organization Tuberculosis Unit, Division of Communicable Disease: Guidelines for Tuberculosis Treatment in Adults and Children in National Treatment Programmes. Geneva, World Health Organization, 1991.
11. Tahaoǧlu K, Ataç G, Sevim T, Tärün T, Yazicioǧlu O, Horzum G, Gemci I, Ongel A, Kapakli N, Aksoy E: The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5:65-69. (Pubitemid 32401878)
12. Moussa LA, Khassouani CE, Soulaymani R, Jana M, Cassanas G, Alric R, Hüe B: Therapeutic isoniazid monitoring using a simple high-performance liquid chromatographic method with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;766:181-187. (Pubitemid 34142390)
13. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE: Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009;29:503-510.
14. Iseman MD: A Clinician's Guide to Tuberculosis. Philadelphia, Lippencott Williams & Wilkins, 2000.
15. Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, Iwakawa S, Okumura K: N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 2001;24:544-549. (Pubitemid 32499483)
16. Peloquin CA: Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-2183.
17. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-889.
18. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952.
19. Ray J, Gardiner I, Marriott D: Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003;33:229-234. (Pubitemid 36718380)
20. Marcel N, Nahta A, Balganesh M: Evaluation of killing kinetics of anti-tuberculosis drugs on Mycobacterium tuberculosis using a bacteriophage-based assay. Chemotherapy 2008;54:404-411.
21. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, Velayati AA: Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol 2004;60:467-471. (Pubitemid 39350159)
22. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M, Milanian I: Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol 2007;34:1207-1211. (Pubitemid 47416363)
23. Weber WW, Hein DW: Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-422. (Pubitemid 10210049)
24. Llorens J, Serrano RJ, Sanchez R: Pharmacodynamic interference between rifampicin and isoniazid. Chemotherapy 1978;24:97-103. (Pubitemid 8251918)